# The Clinical Study of Carrimycin on Treatment Patients With COVID-19

> **NCT04286503** · PHASE4 · UNKNOWN · sponsor: **Beijing YouAn Hospital** · enrollment: 520 (estimated)

## Conditions studied

- Novel Coronavirus Infectious Disease (COVID-19)

## Interventions

- **DRUG:** Carrimycin
- **DRUG:** lopinavir/ritonavir tablets or Arbidol or chloroquine phosphate
- **DRUG:** basic treatment

## Key facts

- **NCT ID:** NCT04286503
- **Lead sponsor:** Beijing YouAn Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-02-23
- **Primary completion:** 2021-02-28
- **Final completion:** 2021-02-28
- **Target enrollment:** 520 (ESTIMATED)
- **Last updated:** 2020-02-27

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04286503

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04286503, "The Clinical Study of Carrimycin on Treatment Patients With COVID-19". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04286503. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*